Physician profile
Patrick Bergin
NPI 1255969630
$4,184.72
in general payments reported to CMS, 2019-2025
24 companies · $1,491 in 2025
The $1,491 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,105 · 2024: $1,589 · 2025: $1,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,184.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $989.68 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $478.84 | 2023-2025 | Repatha, Repatha, Evenity |
| Abbvie INC. | $437.63 | 2023-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $338.66 | 2023-2025 | Rybelsus, Wegovy, Ozempic |
| Glaxosmithkline, LLC. | $261.54 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $240.43 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $188.73 | 2024-2025 | Voquezna |
| Terumo Medical Corporation | $187.19 | 2023-2025 | Azur Cx Detachable |
| Bayer Healthcare Pharmaceuticals INC. | $159.24 | 2023-2025 | |
| Axsome Therapeutics, INC. | $153.71 | 2024-2025 | Auvelity |
| Hydrocision, INC. | $130.08 | 2025 | Tenjet |
| Janssen Pharmaceuticals, INC | $113.07 | 2023 | Xarelto |
| Exact Sciences Corporation | $101.93 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.24 | 2023-2024 | Ofev |
| Biogen, INC. | $56.50 | 2025 | Zurzuvae |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $47.81 | 2023-2024 | Heplisav-B |
| Pfizer INC. | $47.21 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $42.19 | 2023-2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $31.83 | 2023-2025 | |
| Antares Pharma, INC. | $29.05 | 2024-2025 | Xyosted |
| Boston Scientific Corporation | $26.27 | 2025 | Watchman Flx |
| Astellas Pharma US INC | $22.85 | 2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.46 | 2025 | Caplyta |
| Dexcom, INC. | $17.58 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Bergin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.